Andrew Roberts, MSc MBA
Chief Executive Officer
Seasoned pharmaceutical executive with more than 20 years of end-to-end biopharmaceutical R&D and portfolio leadership.
Team
A team that has done every step before: signaling models, assays, chemistry, clinic
Across the team, 100+ publications in the GPCR field and 40+ IND and clinical launches. A lean core of 10+ PhDs from ETH Zurich, the University of Cambridge, Novo Nordisk, Biogen and Pfizer, complemented by senior consultants and CROs and CDMOs. InterAx is a spinoff of ETH Zurich and the Paul Scherrer Institute.
Core team
Dr Aurélien Rizk
Chief Scientific Officer, co-founder
PhD in Computer Science. More than 15 years in the mathematical modeling of cell signaling.
Luca Zenone, MSc
Chief Financial and Operating Officer, co-founder
MSc in Business Administration. Plans, controls and manages all financial, legal and critical operational activities of the company.
Dr Yaroslav Nikolaev
Chief Technology Officer
PhD, with MSc degrees in both biology and computation. More than 15 years of research experience in structural and systems biology.
Dr Charles-Henry Fabritius
Head of Medicinal Chemistry
PhD in Chemistry. More than 18 years of experience in pharmaceutical and biotech companies.
Dr István Szabó
Senior Scientist, machine learning in computational chemistry
PhD in Theoretical and Computational Chemistry. More than 8 years in computational chemistry and cheminformatics.
Dr Tomasz Stepniewski
Senior Scientist, computational chemistry
PhD in Biomedicine.
Nadine Dobberstein, MSc
Laboratory Head, systems biology
BSc in Biology, MSc in Quantitative and Systems Biology.
Dr Florian Wilhelm
Research Scientist, GPCR biophysics
MSc in Biochemistry, PhD in GPCR Biophysics.
Board of Directors
Prof. Dr Jens Gobrecht
Chairman
Professor emeritus of the Laboratory for Micro- and Nanotechnology at the Paul Scherrer Institute, co-founder of Eulitha AG and honorary member of the Swiss Nanoscience Institute.
Dr Aurélien Rizk
Board member
PhD in Computer Science. Co-founder and Chief Scientific Officer of InterAx, co-founder of Algorizk.
Dr Mark Levick, MD
Board member
A 25-year international career with 13 drug approvals. Former CEO of Alvotech, Global Head of Development at Sandoz, Senior Vice President of Global Drug Discovery at Novartis and Vice President of Biopharmaceutical Translational Medicine at GSK.
Dr Yiannis Monovoukas
Board member
Managing Partner at Falcon III and SpringTide Ventures Fund I, and CEO of Helios Cardiovascular and AuraGen Aesthetics.
Dr Bettina Ernst
Board member
CEO of PRECLIN Biosystems, board member of several biotech companies and Vice President of the board of the Swiss Biotech Association.
Scientific advisors
Prof. Gebhard Schertler
Head of the Scientific Advisory Board
Professor emeritus of Structural Biology at ETH Zurich. Former Head of Biology and Chemistry at the Paul Scherrer Institute and coordinator of an ERC Synergy Grant.
Prof. Michel Bouvier
Scientific advisor
Professor of Biochemistry at the Université de Montréal and CEO of the Institute for Research in Immunology and Cancer (IRICoR), Montreal.
Prof. Ruedi Aebersold
Scientific advisor
A pioneer of proteomics and systems biology.
Prof. Jana Selent
Scientific advisor
Associate Professor and Miguel Servet Researcher in the Research Group on Biomedical Informatics (GRIB) at the Hospital del Mar Medical Research Institute (IMIM) and Pompeu Fabra University (UPF).